Prostate Biomarker Study

Summary

Radical Prostatectomy (removal of the prostate) or radiation therapy provide excellent outcomes for patients with localized (confined to one area) disease, yet there is still no effective treatment once the disease has spread beyond the prostate gland. Typically, a serum PSA test is done to diagnose prostate cancer. Following diagnosis, a prostate biopsy and other tests help to classify the patient's disease according to the likelihood of a recurrence. However, these assessments are imperfect. There is a need to identify and evaluate prostate biomarkers that will provide exact information regarding the likelihood of a recurrence (prediction) of prostate cancer.

Conditions

• Prostate Cancer

Interventions

OTHER

Questioners, blood specimens, prostate tissue specimens

You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures. Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat.

OTHER

Questioners, blood specimens, prostate tissue specimens

You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures. Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat.

Sponsors & Collaborators

• Harvard University

  collaborator OTHER

• Baylor College of Medicine

  collaborator OTHER

• Dana-Farber Cancer Institute

  collaborator OTHER

• University of Washington

  collaborator OTHER

• Fred Hutchinson Cancer Center

  collaborator OTHER

• Johns Hopkins University

  collaborator OTHER

• Mayo Clinic

  collaborator OTHER

• M.D. Anderson Cancer Center

  collaborator OTHER

• Northwestern University

  collaborator OTHER

• University of Michigan

  collaborator OTHER

• University of California, San Francisco

  collaborator OTHER

• University of California, Los Angeles

  collaborator OTHER

• Memorial Sloan Kettering Cancer Center

  lead OTHER

Principal Investigators

• James Eastham, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age

35 Years

Sex

MALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2007-05-31

Primary Completion

2011-05-31

Completion

2011-05-31

Countries

• United States

Study Locations